Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial maintenance budesonide-formoterol versus as-needed budesonide-formoterol in newly diagnosed mild asthma
ChiCTR2400088138Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide and formoterol in asthma (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Change in FEV1 from baseline at week 24. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2400088138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088138.